Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anne Lefort is active.

Publication


Featured researches published by Anne Lefort.


Biochemical and Biophysical Research Communications | 1989

Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies.

Frédérick Libert; Anne Lefort; Catherine Gerard; Marc Parmentier; Jason Perret; Marian Ludgate; Jacques Emile Dumont; Gilbert Vassart

A human thyroid cDNA library was screened by hybridization with a dog thyrotropin receptor (TSHr) cDNA. Sequencing of the resulting clones identified a 2292 residue open reading frame encoding a 744 amino acid mature polypeptide presenting 90.3% similarity with the dog TSHr. Two major transcripts (4.6 and 4.4 kilobases) were identified in the human thyroid which suggests that alternative splicing could generate multiple forms of human TSHr. Transfection of the coding sequence in COS-7 cells conferred to a membrane preparation of these cells the ability to bind specifically TSH. TSH binding was completely displaced by immunoglobulin preparations from patients with idiopathic myxoedema.


The EMBO Journal | 1991

The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor.

Frédérick Libert; Serge N. Schiffmann; Anne Lefort; Marc Parmentier; Claude Gérard; Jacques Emile Dumont; Jean-Jacques Vanderhaeghen; Gilbert Vassart

The extensive amino acid sequence conservation among G protein‐coupled receptors has been exploited to clone new members of this large family by homology screening or by PCR. Out of four such receptor cDNAs we cloned recently, RDC7 corresponds to a relatively abundant transcript in the brain cortex, the thyroid follicular cell and the testis. We have now identified RDC7 as an A1 adenosine receptor. The A1 agonist CPA [N6‐cyclopentyladenosine] decreased by 80% cAMP accumulation in forskolin‐stimulated CHO cells stably transfected with RDC7. Specific binding of another A1 adenosine agonist, [3H]CHA [N6‐cyclohexyladenosine], was demonstrated on membranes from Cos cells transfected with a pSVL construct harbouring the RDC7 cDNA insert. The binding characteristics were similar to those of the natural brain A1 receptor. The recombinant and the natural receptors behaved also in the same way in displacement experiments involving a series of A1 adenosine agonists. The binding characteristics of RDC7 were compared to those of RDC8, another orphan receptor recently identified as an A2 adenosine receptor. The two molecular species RDC7 and RDC8 correspond clearly to the A1 and A2 receptor entities defined hitherto on a purely pharmacological basis.


Biochemical and Biophysical Research Communications | 1992

Cloning and functional characterization of a human A1 adenosine receptor.

Frédérick Libert; Jacqueline Van Sande; Anne Lefort; Armin Czernilofsky; Jacques Emile Dumont; Gilbert Vassart; Helmut Ensinger; Klaus Mendla

A human brain hippocampus cDNA library was screened by hybridization with a dog A1 adenosine receptor cDNA probe. Sequencing of the resulting clones identified a 978 residue open reading frame encoding a 326 amino acid polypeptide showing 95.7% similarity with the dog A1 adenosine receptor. Individual clones of stably transfected CHO cells expressing the human A1 receptor were obtained and tested for their response to the A1 agonist CPA [N6-cyclopentyladenosine] in the presence of forskolin. One clone was further characterized with respect to membrane binding of various adenosine agonists and antagonists. The rank order of affinities observed was typical of an A1 adenosine receptor. A Kd value of 2.28 nM was determined using [3H]DPCPX [dipropylcyclopentyl-xanthine], an A1 selective antagonist.


Developmental Biology | 2009

LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine.

Marie-Isabelle Garcia; Mariangela Ghiani; Anne Lefort; Frédérick Libert; Sandra Strollo; Gilbert Vassart

The orphan Leucine-rich repeat G protein-coupled receptor 5 (LGR5/GPR49), a target of Wnt signaling, is a marker of adult intestinal stem cells (SC). However, neither its function in the adults, nor during development of the intestine have been addressed yet. In this report, we investigated the role of LGR5 during ileal development by using LGR5 null/LacZ-NeoR knock-in mice. X-gal staining experiments showed that, after villus morphogenesis, Lgr5 expression becomes restricted to dividing cells clustered in the intervillus region and is more pronounced in the distal small intestine. At day E18.5, LGR5 deficiency leads to premature Paneth cell differentiation in the small intestine without detectable effects on differentiation of other cell lineages, nor on epithelial cell proliferation or migration. Quantitative RT-PCR experiments showed that expression from the LGR5 promoter was upregulated in LGR5-null mice, pointing to the existence of an autoregulatory negative feedback loop in intact animals. This deregulation was associated with overexpression of Wnt target genes in the intervillus epithelium. Transcriptional profiling of mutant mice ileums revealed that LGR5 function is associated with expression of SC and SC niche markers. Together, our data identify LGR5 as a negative regulator of the Wnt pathway in the developing intestine.


EMBO Reports | 2011

Lgr4 is required for Paneth cell differentiation and maintenance of intestinal stem cells ex vivo

Roxana Camelia Mustata; Tom Van Loy; Anne Lefort; Frédérick Libert; Sandra Strollo; Gilbert Vassart; Marie-Isabelle Garcia

Gene inactivation of the orphan G protein‐coupled receptor LGR4, a paralogue of the epithelial‐stem‐cell marker LGR5, results in a 50% decrease in epithelial cell proliferation and an 80% reduction in terminal differentiation of Paneth cells in postnatal mouse intestinal crypts. When cultured ex vivo, LGR4‐deficient crypts or progenitors, but not LGR5‐deficient progenitors, die rapidly with marked downregulation of stem‐cell markers and Wnt target genes, including Lgr5. Partial rescue of this phenotype is achieved by addition of LiCl to the culture medium, but not Wnt agonists. Our results identify LGR4 as a permissive factor in the Wnt pathway in the intestine and, as such, as a potential target for intestinal cancer therapy.


Cell Reports | 2015

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Debora Fumagalli; David Gacquer; Françoise Rothé; Anne Lefort; Frédérick Libert; David Norman Brown; Naima Kheddoumi; Adam Shlien; Tomasz Konopka; Roberto Salgado; Denis Larsimont; Kornelia Polyak; Karen Willard-Gallo; Christine Desmedt; Martine Piccart; Marc Abramowicz; Peter J. Campbell; Christos Sotiriou; Vincent Detours

Summary Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and cancerous breast tissues revealed that the editing enzyme ADAR acts uniformly, on the same loci, across tissues. In controlled ADAR expression experiments, the editing frequency increased at all loci with ADAR expression levels according to the logistic model. Loci-specific “editabilities,” i.e., propensities to be edited by ADAR, were quantifiable by fitting the logistic function to dose-response data. The editing frequency was increased in tumor cells in comparison to normal controls. Type I interferon response and ADAR DNA copy number together explained 53% of ADAR expression variance in breast cancers. ADAR silencing using small hairpin RNA lentivirus transduction in breast cancer cell lines led to less cell proliferation and more apoptosis. A-to-I editing is a pervasive, yet reproducible, source of variation that is globally controlled by 1q amplification and inflammation, both of which are highly prevalent among human cancers.


Human Molecular Genetics | 2012

Kinetochore KMN network gene CASC5 mutated in primary microcephaly

Anne Genin; Julie Désir; Nelle Lambert; Martine Biervliet; Nathalie Van der Aa; Geneviève Pierquin; Audrey Killian; Mario Tosi; Montse Urbina; Anne Lefort; Frédérick Libert; Isabelle Pirson; Marc Abramowicz

Several genes expressed at the centrosome or spindle pole have been reported to underlie autosomal recessive primary microcephaly (MCPH), a neurodevelopmental disorder consisting of an important brain size reduction present since birth, associated with mild-to-moderate mental handicap and no other neurological feature nor associated malformation. Here, we report a mutation of CASC5 (aka Blinkin, or KNL1, or hSPC105) in MCPH patients from three consanguineous families, in one of which we initially reported the MCPH4 locus. The combined logarithm of odds score of the three families was >6. All patients shared a very rare homozygous mutation of CASC5. The mutation induced skipping of exon 18 with subsequent frameshift and truncation of the predicted protein. CASC5 is part of the KMN network of the kinetochore and is required for proper microtubule attachment to the chromosome centromere and for spindle-assembly checkpoint (SAC) activation during mitosis. Like MCPH gene ASPM, CASC5 is upregulated in the ventricular zone (VZ) of the human fetal brain. CASC5 binds BUB1, BUBR1, ZWINT-1 and interestingly it binds to MIS12 through a protein domain which is truncated by the mutation. CASC5 localized at the equatorial plate like ZWINT-1 and BUBR1, while ASPM, CEP152 and PCTN localized at the spindle poles in our patients and in controls. Comparison of primate and rodent lineages indicates accelerated evolution of CASC5 in the human lineage. Our data provide strong evidence for CASC5 as a novel MCPH gene, and underscore the role of kinetochore integrity in proper volumetric development of the human brain.


European Journal of Immunology | 2008

Modulation of murine dendritic cell function by adenine nucleotides and adenosine: Involvement of the A2B receptor

Abduelhakem Ben Addi; Anne Lefort; Xiaoyang Hua; Frédérick Libert; Didier Communi; Catherine Ledent; Pascale Macours; Stephen L. Tilley; Jean-Marie Boeynaems; Bernard Robaye

Adenosine triphosphate has previously been shown to induce semi‐mature human monocyte‐derived dendritic cells (DC). These are characterized by the up‐regulation of co‐stimulatory molecules, the inhibition of IL‐12 and the up‐regulation of some genes involved in immune tolerance, such as thrombospondin‐1 and indoleamine 2,3‐dioxygenase. The actions of adenosine triphosphate are mediated by the P2Y11 receptor; since there is no functional P2Y11 gene in the murine genome, we investigated the action of adenine nucleotides on murine DC. Adenosine 5′‐(3‐thiotriphosphate) and adenosine inhibited the production of IL‐12p70 by bone marrow‐derived DC (BMDC). These inhibitions were relieved by 8‐p‐sulfophenyltheophylline, an adenosine receptor antagonist. The use of selective ligands and A  2B–/– BMDC indicated the involvement of the A2B receptor. A microarray experiment, confirmed by quantitative PCR, showed that, in presence of LPS, 5′‐(N‐ethylcarboxamido) adenosine (NECA, the most potent A2B receptor agonist) regulated the expression of several genes: arginase I and II, thrombospondin‐1 and vascular endothelial growth factor were up‐regulated whereas CCL2 and CCL12 were down‐regulated. We further showed that NECA, in combination with LPS, increased the arginase I enzymatic activity. In conclusion, the described actions of adenine nucleotides on BMDC are mediated by their degradation product, adenosine, acting on the A2B receptor, and will possibly lead to an impairment of Th1 response or tolerance.


Journal of Investigative Dermatology | 2009

Genotypic and Gene Expression Studies in Congenital Melanocytic Nevi: Insight into Initial Steps of Melanotumorigenesis

Barbara Dessars; Linda De Raeve; Renato Morandini; Anne Lefort; Hakim El Housni; Ghanem Elias Ghanem; Benoı̂t J. Van den Eynde; Wenbin Ma; Diane Roseeuw; Gilbert Vassart; Frédérick Libert; Pierre Heimann

Large congenital melanocytic nevi (CMNs) are said to have a higher propensity to malignant transformation compared with acquired nevi. Thus, they represent a good model for studying initial steps of melanotumorigenesis. We have performed genotypic (karyotype, fluorescence in situ hybridization, and mutational analyses) and differential expression studies on a large cohort of medium (n=3) and large (n=24) CMN. Chromosomal abnormalities were rare and single, a feature probably reflecting the benignity of these lesions. Mutational screening showed a high frequency of NRAS mutations in our series (19/27 cases, 70%), whereas BRAF mutations were less common (4/27 cases, 15%). Differential did not show significant alterations of cellular processes such as cell proliferation, cell migration/invasion, angiogenesis, apoptosis, and immune/inflammatory responses. However, significant downregulation of genes involved in pigmentation and upregulation of genes playing a role in DNA protection were observed. Lastly, our microarrays displayed upregulation of genes mediating chemoresistance in cancer. As alteration of pigmentation mechanisms can trigger oxidative damage, increased expression of genes involved in maintenance of DNA integrity might reflect the ability of nevocytic cells to self-protect against cellular stress. Furthermore, the observed alterations linked to chemoresistance might partially account for the well-known inefficacy of chemotherapy in malignant melanoma.


Cytogenetic and Genome Research | 1990

Localization of human thyrotropin receptor gene to chromosome region 14q31 by in situ hybridization

Frédérick Libert; Edith Passage; Anne Lefort; Gilbert Vassart; M. G. Mattei

The gene for human thyrotropin receptor (TSHR) was assigned to chromosome J4, band q31, by in situ hybridization, using a probe for TSHR

Collaboration


Dive into the Anne Lefort's collaboration.

Top Co-Authors

Avatar

Frédérick Libert

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Gilbert Vassart

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Jacques Emile Dumont

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Marc Parmentier

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Jacqueline Van Sande

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Daniel Christophe

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Marc Abramowicz

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Catherine Gerard

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar

Jason Perret

Free University of Brussels

View shared research outputs
Top Co-Authors

Avatar

Marie-Isabelle Garcia

Université libre de Bruxelles

View shared research outputs
Researchain Logo
Decentralizing Knowledge